Where does GPN Vaccines's cap table come from?

Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across GPN Vaccines's 1 recorded funding rounds.

Premier Alternatives

GPN Vaccines

Canberra, Australia · Founded 2017 · Privately Held (backing)

Developer of vaccines intended to offer protection against pneumococcal bacteria, the world's foremost bacterial pathogen. GPN Vaccines is based in Canberra, Australia and was founded in 2017. Its last reported valuation was $300 million in Jun 2024. It has raised $27.7 million across 1 recorded round; the latest was a $3.5 million seed round in Dec 2025.

Last reported valuation

$300.0M

Oct 2026

Priced at

—

Total raised

$27.7M

Last round

Seed Round

Dec 2025

Cap table — not yet on record

GPN Vaccines's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.

Pro members can request priority coverage with a 48-hour turnaround.

Free account

More of GPN Vaccines with a free account

·Watch GPN Vaccines: the Monday email on marks, rounds and moves

Create free account

No card required

Membership and data by Private Market View

Frequently asked about GPN Vaccines

Where does GPN Vaccines's cap table come from?: Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across GPN Vaccines's 1 recorded funding rounds.